Sorrento Therapeutics Selects OmniComm’s TrialMaster® EDC for Cancer Research
Fort Lauderdale, FL, September 20, 2018 - Sorrento Therapeutics, Inc. (Nasdaq: SRNE), a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases, has signed a new agreement with OmniComm Systems, Inc. (OTCQX: OMCM), a leading global provider of clinical data management technology. Under the agreement, Sorrento will use OmniComm’s TrialMaster EDC technology to develop clinical studies at multiple Sorrento research sites.
“We are honored and thrilled that the Sorrento management team has selected OmniComm’sTrialMaster platform with its advanced EDC and eSource technology to accelerate their cancer research efforts,” said Kuno van der Post, Ph.D., chief commercial officer, OmniComm Systems.
About Sorrento Therapeutics, Inc.
Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms,including key assets such as fully human antibodies (“G-MABTM library”), clinical stage immuno-cellulartherapies (“CAR-T”), intracellular targeting antibodies (“iTAbs”), antibody-drug conjugates (“ADC”), andclinical stage oncolytic virus (“Sephrevir®”). Sorrento's commitment to life-enhancing therapies for cancer patients is also demonstrated by the effort to advance a first-in-class (TRPV1 agonist) non-opioidpain management small molecule in Resiniferatoxin (“RTX”) and ZTlidoTM. Resiniferatoxin is completing aphase IB trial in terminal cancer patients. ZTlido was approved by US FDA on 02/28/18. For more information, visit www.sorrentotherapeutics.com
About OmniComm Systems, Inc.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry.OmniComm is dedicated to helping the world’s pharmaceutical, biotechnology, contract researchorganizations, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies, these organizations drive efficiency in clinical development, better manage their risks, ensure regulatory compliance and manage their clinical operations performance. With an extensive global experience from more than 6,000 clinical trials, OmniComm provides comprehensive solutions for clinical research. Please visit www.omnicomm.com for more information.
Trademarks
OmniComm, TrialMaster and TrialOne are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.
Contact Info
Kuno van der Post
OmniComm Systems, Inc.
+1.954.473.1254
KvanderPost@omnicomm.com
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.
